

CONTENTS

Tables and Figures	9
Appendices	9
Foreword	11
SECTION: 1	15
1 Epidemiology of Opioid Use in Tasmania	15
1.1 Overview	15
1.2 The Tasmanian perspective	16
SECTION: 2	21
2 Clinical Features of Opioid Dependence	21
2.1 Definition of opioid dependence	21
2.2 Signs and Symptoms of Opioid Withdrawal, Intoxication and Overdose	22
2.3 Definition of opioid withdrawal	23
2.4 Opioid intoxication and Overdose	24
2.5 Implications for the current guidelines	25
SECTION: 3	29
3 Policy Framework	29
3.1 Principles of Harm Minimisation	29
3.2 Biopsychosocial approach	30
3.3 Evidence based practice	31
3.4 Rationale for opioid pharmacotherapy	31
3.5 Aims of opioid pharmacotherapy treatment	32
3.6 Priority access	33
3.7 Evidence for effectiveness of various opioid pharmacotherapies	33
3.8 Key principles for effective treatment	34
3.9 How opioid pharmacotherapy is provided in Tasmania	35
3.10 Shared Care Model	36
3.11 Tasmanian Shared Care Model	37
SECTION: 4	43
4 Clinical Pharmacology	43
4.1 Basic Opioid Pharmacology	43
4.2 Methadone	44
4.3 Buprenorphine	49
4.4 Indication for Opioid Pharmacotherapy	55
4.5 General Contraindications and Precautions for Opioid Pharmacotherapy	56
4.6 Comparing Treatment Options	57
4.7 Gateway Model - Buprenorphine as Induction Agent of Choice	62
SECTION: 5	67
5 Assessment for Entry into the Opioid Pharmacotherapy Program	67
5.1 Assessment	67
5.2 Initial Assessment	67
5.3 Substance Use History	69
5.4 Past Medical History	71
5.5 Psychological and Psychiatric History	72
5.6 Social History	73

5.7	Family History.....	74
5.8	Pregnancy and Breastfeeding.....	75
5.9	Allergies.....	76
5.10	Clinical Examination.....	76
5.11	Investigations.....	77
5.12	Urine drug screening (UDS) during assessment.....	77
5.13	Collateral Information.....	78
5.14	Summary and Formulation.....	79
5.15	Additional Consideration - Harm Reduction Advice.....	79
SECTION: 6.....		83
6	Entry Into Opioid Pharmacotherapy.....	83
6.1	Preparing the Patient.....	83
6.2	Code of Conduct and Involuntary Discharge.....	88
6.3	Administrative Requirements for Entry into Treatment.....	88
6.4	Alcohol and Drug Services Treatment Agreement.....	94
6.5	Creating a Patient File.....	94
6.6	Information Pack.....	94
SECTION: 7.....		97
7	Safe Treatment Induction.....	97
7.1	Induction to Opioid Treatment.....	97
7.2	Induction to methadone pharmacotherapy.....	99
7.3	Induction to buprenorphine pharmacotherapy.....	104
7.4	Alternative Treatment Options.....	107
7.5	Patient Reviews.....	108
7.6	Dosing Location.....	109
7.7	Methadone and Buprenorphine Dosing Procedure.....	109
7.8	Moving to maintenance.....	110
SECTION: 8.....		114
8	Maintenance Treatment.....	114
8.1	Methadone.....	114
8.2	Buprenorphine.....	115
8.3	Ongoing Review.....	116
8.4	Urine drug screening during maintenance.....	116
8.5	Takeaway Doses: general considerations.....	117
8.6	Methadone takeaway doses.....	120
8.7	Buprenorphine dosing schedules and takeaway doses.....	123
8.8	Missed Doses.....	128
8.9	Lost or Stolen Doses.....	134
8.10	Vomited Doses.....	134
8.11	Continued Use of Other Drugs.....	135
8.12	Transferring Between Treatment Agents.....	136
SECTION: 9.....		141
9	Completing Treatment.....	141
9.1	Planned and Voluntary Withdrawal from Opioid Pharmacotherapy.....	141
9.2	Withdrawal from Treatment Plan.....	141
9.3	Rapid Withdrawal from Opioid Pharmacotherapy.....	146
9.4	Avoiding secondary problems with alcohol, sedative or hypnotic drugs.....	147
9.5	Exiting patients.....	148
SECTION: 10.....		153
10	Psychosocial interventions in opioid pharmacotherapy.....	153

10.1	Psychosocial and Social Issues in Substance Use.....	153
10.2	Types of Psychosocial Interventions in Opioid Pharmacotherapy.....	155
10.3	Applying Psychosocial interventions across the pharmacotherapy treatment spectrum	157
10.4	Benefits of Including Psychosocial Interventions.....	159
SECTION: 11.....		163
11	Specific Populations Receiving Opioid Pharmacotherapy.....	163
11.1	Comorbid Mental Health Disorders	163
11.2	Cognitive Impairment	167
11.3	Working with Families and Significant Others.....	168
11.4	Female Clients	168
11.5	Pregnancy	169
11.6	Management of neonatal care	175
11.7	Blood- borne viruses.....	176
11.8	Culturally sensitive practice.....	178
11.9	Young people	180
11.10	Recently released prisoners.....	182
SECTION: 12.....		185
12	Managing Complex Presentations.....	185
12.1	Consultation and liaison services	185
12.2	Managing hospitalised clients with opioid dependence	185
12.3	Managing Acute Pain in Primary Care.....	190
12.4	Persistent Pain.....	191
12.5	Therapeutic Dependence	191
12.6	Section 59E: Addiction Medicine Review.....	193
12.7	Sudden Cessation of Opioid Pharmacotherapy	194
12.8	Managing Aggression and Threatening Behaviour	195
12.9	Continued High Risk Drug Use and Polydrug Use.....	198
12.10	Drug Dependent Behaviours.....	200
12.11	Involuntary Removal from the Opioid Pharmacotherapy Program.....	205
12.12	Public Safety Issues	206
12.13	Managing Overdose.....	208
12.14	Boundary Violation and Boundary Crossing	210
12.15	Professional Reporting	210
SECTION: 13.....		215
13	Transfers	215
13.1	Prescribing across Australian jurisdictions	215
13.2	Clients Travelling to Tasmania	215
13.3	Intrastate Transfers of Tasmanian opioid pharmacotherapy clients.....	220
13.4	Interstate transfers of Tasmanian opioid pharmacotherapy clients.....	222
13.5	Overseas travel	226
13.6	Transfer of Dosing Location.....	227
13.7	Unsanctioned Transfers	228
SECTION: 14.....		233
14	Legislative requirements	233
14.1	Poisons Act 1971	233
14.2	Alcohol and Drug Dependence Act 1968.....	234
14.3	Mental Health Act 1996.....	234
14.4	Misuse of Drugs Act 2001	235
14.5	Guardianship Administration Act 1995.....	236
14.6	Children, Young Persons and Their Families Act 1997	236

14.7	Family Violence Act 2004	237
14.8	Personal Information Protection Act 2004	238
14.9	Right to Information Act 2010.....	239
14.10	Firearms Act 1996	240
14.11	Vehicle and Traffic Act 1999	241
14.12	Health Practitioners Regulation National Law (Tasmania) Act 2010.....	242
SECTION: 15.....		247
15	Prescriber Training and Authorisation	247
15.1	Process of prescriber authorisation	247
15.2	Regulations relating to pharmacotherapy prescribing	248
SECTION: 16.....		255
16	Pharmacy Instructions	255
16.1	Approval and Accreditation to Dose	255
16.2	Patient Orientation to a Community Pharmacy	258
16.3	Dosing Procedure.....	258
16.4	Regulatory Requirements	265
16.5	Dosing Errors.....	268
16.6	Dosing Challenges	269
16.7	Financial Considerations	276
16.8	Documentation.....	277
Acronyms.....		281
References		283
Recommended Reading.....		297

Tables and Figures

Table 2.1	Signs and Symptoms of Opioid Withdrawal, Intoxication and Overdose
Table 4.1	Summary of Methadone Pharmacokinetics
Table 4.2	Effects of Methadone
Table 4.3	Summary of Buprenorphine Pharmacokinetics
Table 4.4	Pharmacological Comparisons Between Methadone and Buprenorphine
Table 8.1	Guidelines for Methadone Dosing and Authorisation at Various Doses
Table 8.2	Guidelines for the Provision of Methadone Takeaway Doses
Table 8.3	Guidelines for Buprenorphine Takeaway Doses for Patients on Daily Dosing Schedules
Table 9.1	Recommended Methadone Dose Reductions
Table 9.2	Recommended Buprenorphine Dose Reductions
Table 9.3	Suggested Dosing Regimen for Rapid Withdrawal From Methadone
Table 9.4	Suggested Dosing Regimen for Withdrawal From Buprenorphine
Figure 3.1	Biopsychosocial Theoretical Approach (Engel, 1977)
Figure 4.1	Opiate Effects of Full Agonists, Partial and Antagonist
Figure 4.2	Methadone Molecule
Figure 4.3	Buprenorphine Molecule
Figure 7.1	Plasma Concentration After a Single Dose of Oral Methadone
Figure 7.2	Plasma Concentrate After Three Daily Doses on Oral Methadone
Figure 7.3	Plasma Concentration Once Steady State Achieved on Oral Methadone
Figure 8.1	Three Day Recovery to Steady State From Missed Dose at Day 10
Figure 10.1	Tasmanian Alcohol and Drug Services Pharmacotherapy Services Delivery Mode: Phases of Opioid Pharmacotherapy
Figure 12.1	Section 59E Model
Figure 3.1 5.1	Prescribing S8 Opioids and Drugs of Dependence Quick Reference Guide

Appendices

Appendices will be added in at a later stage.

Section	Description
4.2.5	
4.3.5	
4.5.4	
6.3.1	
6.4	
6.5	
7.3	
8.7.5	